In order to access the Charts, please log on to your TD Ameritrade account or open an account!
Arvinas IncChange company Symbol lookupSelect an option...ARVN Arvinas IncPAYX Paychex IncPYR Pyrogenesis Canada IncPM Philip Morris International IncGWAV Greenwave Technology Solutions IncSLNO Soleno Therapeutics IncVRPX Virpax Pharmaceuticals IncFDCFF Forum Energy Metals CorpAFMD Affimed NVFOUR Shift4 Payments IncGo
Change company Symbol lookup
Select an option...
ARVN Arvinas Inc
PAYX Paychex Inc
PYR Pyrogenesis Canada Inc
PM Philip Morris International Inc
GWAV Greenwave Technology Solutions Inc
SLNO Soleno Therapeutics Inc
VRPX Virpax Pharmaceuticals Inc
FDCFF Forum Energy Metals Corp
AFMD Affimed NV
FOUR Shift4 Payments Inc
Health Care : Pharmaceuticals | Small Cap Blend
Company profileArvinas, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. The Company uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three product candidates include ARV-110, ARV-471 and ARV-766. It develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). It develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. The Company develops ARV-766, a PROTAC protein degrader for the treatment of men with mCRPC.
|
|
|
|
| |
Please Log On
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.
Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.